Increased ROS production by the NADPH oxidase (NOX) family of enzymes in acute leukemias, particularly FLT3-ITD AML, has been increasingly studied over the last few years, and highlights that elevated ROS is a mechanism conferring survival advantages in FLT3-mutant AML [53–56]. The gene discussed is FMO5; the disease is acute myeloid leukemia.